Aleksandra Opinc-Rosiak
Aleksandra is a trainee in rheumatology at the USK-WAM Hospital, research and teaching assistant at the Medical University of Lodz, Poland. Her major interests are idiopathic inflammatory myopathies, in particular antisynthetase syndrome, and autoantibodies. Aleksandra is a member of the Newsletter Sub-Committee
| Poster 0627 | Sunday, 12.11.23 09:00 Poster Session A (Systemic Sclerosis & Related Disorders – Clinical Poster I: Research) Author: Burja, B (Switzerland) Title: CLINICAL SIGNIFICANCE OF ANTI-RO/SSA ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR DATABASE  Based on the EUSTAR database, anti-SSA antibodies were found to be associated with more severe lung involvement in the course of systemic sclerosis. |
| Poster 0668 | Sunday, 12.11.23 09.00 Poster Session A (Systemic Sclerosis & Related Disorders – Clinical Poster I: Research) Author: Hwang, J (South Korea) Title: INCREASED RISK OF CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: A POPULATION-BASED STUDY Patients with systemic sclerosis have 1.5 times higher risk of cancer as compared to general population. The overall cancer incidence rate was 11.07 per 1000 person-years in patients with systemic sclerosis. |
| Poster 1239 | Sunday, 12.11.23 09:00 Poster Session A (Vasculitis – ANCA-Associated Poster I: Treatment Outcomes) Author: Geetha, D (USA) Title: EFFICACY AND SAFETY OF AVACOPAN IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS RECEIVING RITUXIMAB IN A PHASE 3 TRIAL Results of ADVOCATE trial proved the efficacy of avacopan for achieving and sustaining remission in patients with ANCA-associated vasculitis treated with RTX. |
| Oral 1648 | Monday, 13.11.23 14.00 Abstract Session (Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging) Author: Dejaco, C (Italy) Title: EULAR RECOMMENDATIONS FOR THE USE OF IMAGING IN LARGE VESSEL VASCULITIS IN CLINICAL PRACTICE: 2023 UPDATE Summary of the latest recommendations for the use of imaging in large vessel vasculitis. First lines therapies recommended: US in patients with suspected GCA and MRI for Takayasu arteritis. |
| Oral 1699 | Monday, 13.11.23 16.00 Abstract Session (Systemic Sclerosis & Related Disorders II: Clinical Research) Author: Bruno, C (Switzerland) Title: IMMUNOSUPPRESSION WITH TARGETED THERAPIES REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS Targeted therapies were found to reduce the risk of mortality and pre-capillary pulmonary hypertension worsening in patients with systemic sclerosis. |
| Oral 2462 | Tuesday, 13.11.23 14:00 Abstract Session (Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I) Author: Gonzalez-Chapa, J (USA) Title: MITOCHONDRIAL-MEDIATED NEUTROPHIL ACTIVATION IN DERMATOMYOSITIS (DM) AND INCLUSION BODY MYOSITIS (IBM): INSIGHTS INTO PATHOGENESIS AND THERAPEUTIC IMPLICATIONS Novel biomarkers, potentialy indicating the roles of mitochondria and neutrophils, have been identified in IIM. Calprotectin and NETs may play distinct roles in DM and IBM, while mitochondrial dysfunction 3ay be considered as a common pathological mechanism. |